Atnaujinkite slapukų nuostatas

Fungal Infections in the Immunocompromised Patient [Kietas viršelis]

Edited by (University of Florida, Gainesville, Florida, USA), Edited by
  • Formatas: Hardback, 698 pages, aukštis x plotis: 254x178 mm, weight: 1383 g
  • Išleidimo metai: 05-Aug-2005
  • Leidėjas: CRC Press Inc
  • ISBN-10: 082475428X
  • ISBN-13: 9780824754280
Kitos knygos pagal šią temą:
Fungal Infections in the Immunocompromised PatientDidesnis paveikslėlis
  • Formatas: Hardback, 698 pages, aukštis x plotis: 254x178 mm, weight: 1383 g
  • Išleidimo metai: 05-Aug-2005
  • Leidėjas: CRC Press Inc
  • ISBN-10: 082475428X
  • ISBN-13: 9780824754280
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780824754280.html
Raktažodžiai:
Unlike any other source on the subject, this reference provides an up-to-date account of fungal syndromes in immunocompromised patients and provides expert descriptions of their clinical manifestations and settings in which they cause illness-covering the pros and cons of current and emerging diagnostic measures, techniques to incorporate new diagnostic tools and treatments into established clinical practices, and the most recent therapeutic strategies in patient care.
Preface iii
Contributors xv
Overview of Host Defenses: Innate and Acquired Immunity
1(44)
Monica Grazziutti
Elias J. Anaissie
John R. Wingard
Introduction
1(1)
Innate Immunity
1(17)
Acquired Immunity
18(8)
Host Defenses Against the Most Common Fungi in Immunocompromised Hosts
26(8)
Conclusion
34(11)
References
34(11)
Impact of Invasive Fungal Infection on Patients Undergoing Solid Organ Transplantation
45(30)
Francisco M. Marty
Lindsey R. Baden
Robert H. Rubin
Introduction
45(2)
Invasive Fungal Infection in Solid Organ-Transplant Patients
47(1)
Risk of Invasive Fungal Infection in the Solid Organ-Transplant Recipient
48(4)
Temporal Aspects of Fungal Infection in the Solid Organ-Transplant Recipient
52(3)
Fungal Infections of Importance in the Organ-Transplant Recipient
55(10)
Principles of Antifungal Therapy in Solid Organ-Transplant Recipients
65(6)
Summary and Conclusions
71(4)
References
71(4)
Fungal Infections in Blood and Marrow Transplant Recipients
75(22)
Kieren A. Marr
Introduction
75(1)
Fungal Infections: Overall Incidence and Risks
75(11)
Conclusion
86(11)
References
87(10)
Assessment of the Risk for Invasive Fungal Infection Among Oncology Patients
97(32)
E. J. Bow
Introduction
97(1)
Epidemiology of Invasive Fungal Infection Observed at Autopsy
97(4)
Superficial and Invasive Candidiasis
101(4)
Invasive Filamentous Fungal Infection
105(2)
Colonization
107(1)
Myelosuppression and Immunosuppression
108(5)
Cytotoxic Therapy-Induced Mucosal Injury and Invasive Fungal Infection
113(16)
References
114(15)
Epidemiology of Fungal Infection in Patients with Human Immunodeficiency Virus
129(20)
Anucha Apisarnthanarak
William G. Powderly
Introduction
129(1)
Specific Fungal Infections
129(9)
Special Considerations in HIV-Infected Patients
138(2)
Conclusion
140(9)
References
140(9)
Candida Infections in the Intensive Care Unit
149(36)
Joseph S. Solomkin
Introduction
149(1)
Pathogenicity and Virulence Factors for Candida
149(1)
The Microbiology, Incidence, Morbidity, and Mortality of Candida Infection
150(3)
Clinical Aspects of Candida Infection
153(4)
Who Should Receive Antifungal Prophylaxis in the ICU?
157(3)
Special Populations at Risk of Candida Infections and Possibly Meriting Prophylaxis
160(2)
Management of Specific Infections
162(2)
Catheter Management in Candidemic Patients
164(1)
Descriptions of Specific Agents
165(5)
Recommendations for Therapy---A Care Path
170(1)
Other Sites of Candida Infections
171(3)
Conclusions
174(11)
References
174(11)
Fungal Infections in Immunocompromised Hosts: Host Defenses, Risks, and Epidemiology in Special Patient Groups---Pediatrics
185(14)
Charles B. Foster
Stephen J. Chanock
Introduction
185(2)
Specific Fungal Infections
187(12)
References
193(6)
Clinical Manifestations of Invasive Fungal Infections
199(16)
Ben E. de Pauw
Jacques F.G.M. Meis
Unexplained Fever
199(2)
Bronchopneumonia
201(4)
Skin Lesions
205(2)
Sinusitis and Central Nervous System Disease
207(2)
Disseminated Disease and Miscellaneous Issues
209(6)
References
210(5)
Clinical Syndromes by Candida Species
215(42)
Maria Cecilia Dignani
Introduction
215(1)
The Pathogen
215(1)
Epidemiology
216(2)
Pathogenesis
218(1)
Syndromes
218(13)
Diagnosis
231(2)
Therapy
233(6)
Prevention
239(18)
References
242(15)
Aspergillosis
257(38)
William J. Steinbach
Juergen Loeffler
David A. Stevens
Etiology and Epidemiology
257(1)
Syndromes
258(4)
Diagnosis
262(7)
Therapy
269(26)
References
278(17)
Endemic Mycoses Fungal Infections in Immunocompromised Patients
295(16)
Robert W. Bradsher
Introduction
295(11)
Summary
306(5)
References
307(4)
Emerging Fungal Infections
311(30)
Rhonda V. Fleming
Elias J. Anaissie
Introduction
311(1)
Emerging Yeasts
311(5)
Emerging Filamentous Fungi
316(9)
Dematiaceous Molds
325(2)
Cryptococcus spp
327(2)
Conclusion
329(12)
References
330(11)
Conventional Methods for the Laboratory Diagnosis of Fungal Infections in the Immunocompromised Host
341(42)
Michael A. Pfaller
Sandra S. Richter
Daniel J. Diekema
Introduction
341(2)
Clinical Recognition of Fungal Infection
343(1)
Spectrum of Opportunistic Fungal Pathogens
344(1)
Conventional Methods for the Laboratory Diagnosis of Fungal Infections
344(29)
Antifungal Susceptibility Testing
373(3)
Summary and Conclusions
376(7)
References
376(7)
Serological and Molecular Approaches to the Diagnosis of Invasive Fungal Infections in Immunocompromised Patients
383(24)
Jose L. Lopez-Ribot
Thomas F. Patterson
Introduction
383(1)
Serodiagnosis of Invasive Candidiasis
384(4)
Serodiagnosis of Invasive Aspergillosis
388(3)
Detection of Fungal Metabolites and Other Nonantigenic Components
391(1)
PCR-Based Diagnosis
392(3)
Nonculture Based Diagnosis of Pathogenic and Endemic Mycoses
395(1)
Summary
396(11)
References
397(10)
Radiology of Fungal Infections in the Immunocompromised Patient
407(22)
Reginald Greene
Overview
407(1)
Clinical-Etiologic Constellations
408(1)
Imaging Techniques
409(1)
Imaging in Specific Invasive Mycoses
410(14)
Summary
424(5)
References
425(4)
Polyenes
429(28)
John Hiemenz
Thomas J. Walsh
Introduction
429(1)
Amphotericin B Deoxycholate
430(3)
Lipid Formulations of Amphotericin B
433(24)
References
448(9)
The Systemically Acting Azoles
457(28)
Paul O. Gubbins
Introduction
457(1)
Mechanism of Action
458(9)
In Vitro Activity
467(5)
Mechanisms of Resistance to Azoles
472(1)
In Vivo Experimental Activity
473(2)
Clinical Efficacy of the Azoles
475(3)
Drug Interactions
478(1)
Conclusion
478(7)
References
479(6)
Echinocandin Antifungal Drugs
485(24)
John R. Graybill
Gregory M. Anstead
A New Antifungal Target
485(1)
Mechanism of Action
486(2)
Correlating In Vitro and In Vivo Activity
488(3)
Clinical Evaluation: How Are These Drugs Handled?
491(3)
Clinical Efficacy
494(5)
Combination Therapy of Mycoses
499(2)
A Footnote on Pneumocystis
501(8)
References
501(8)
Antifungal Agents: Other Classes and Compounds
509(20)
Andreas H. Groll
Thomas J. Walsh
Agents for Systemic Treatment of Invasive Mycoses
509(5)
Cell Wall Active Agents
514(1)
Cell Membrane Active Agents
515(2)
Agents for Systemic Treatment of Mycoses of the Skin and Its Appendages
517(3)
Topical Antifungal Agents
520(9)
References
521(8)
Clinically Relevant Drug Interactions with Systemic Antifungal Therapy
529(38)
Helen L. Leather
Introduction
529(3)
Drug-Drug Interactions
532(22)
Conclusion
554(13)
References
554(13)
Adjunctive Immunotherapy Against Opportunistic Fungal Infections
567(34)
Emmanuel Roilides
John Dotis
Thomas J. Walsh
Introduction
567(1)
Overview of Antifungal Host Defenses
568(1)
Rationale of Adjunctive Immunotherapy
569(1)
Preclinical Basis of Immunotherapy
570(10)
Recommendations for the Use of HGFs and Cytokines in the Prevention and Treatment of IFIs in Immunocompromised Patients
580(3)
White Blood Cell Transfusions (WBCTx)
583(3)
Other Modes of Adjunctive Immunotherapy
586(1)
Future Directions
587(1)
Conclusions
588(13)
References
588(13)
Antifungal Prophylaxis
601(20)
John R. Wingard
Elias J. Anaissie
Rationale
601(1)
Types of Prophylaxis
602(1)
Candida
603(4)
Aspergillus
607(2)
Cryptococcus
609(1)
Histoplasmosis
610(1)
Coccidioides
610(1)
Pneumocystis jiroveci
611(1)
Duration of Prophylaxis
611(1)
Infection Control
612(1)
Conclusions
613(8)
References
613(8)
Empirical Therapy of Suspected Infections
621(16)
J. A. Maertens
K. Theunissen
M. A. Boogaerts
Introduction
621(1)
Rationale and Goal of Empirical Therapy
622(1)
Historical Perspective of Empirical Antifungal Therapy
623(1)
The Evolving Empirical Arsenal
624(4)
Towards Preemptive or Early-Therapy Strategies
628(1)
Future Perspectives
629(1)
Conclusion
630(7)
References
630(7)
Treatment of Invasive Fungal Infections
637(30)
John R. Wingard
Elias J. Anaissie
Introduction
637(1)
Candidiasis
637(5)
Aspergillosis
642(4)
Cryptococcus
646(5)
Histoplasmosis
651(2)
Coccidiodomycosis
653(1)
Other Fungi
653(2)
Pneumocystis jiroveci (Formerly Pneumocystis carinii)
655(1)
Conclusion
656(11)
References
656(11)
Index 667(8)
About the Editors 675


John R. Wingard, Elias J. Anaissie